Early Alphabetic Inscriptions from Eretria, Greece: 8th Cent. BC Graffiti from the Sanctuary of Apollo Daphnephoros

La transmission de l'alphabet aux Grecs est un sujet encore très débattu. Les plus anciennes inscriptions alphabétiques grecques datent du VIIIe s. av. J.-C. et une majorité d'entre elles a été trouvée dans des sites eubéens. Une trentaine a été mise au jour à Erétrie, dont 26 proviennent du sanctuaire d'Apollon Daphnéphoros. Ces inscriptions, pour la plupart inscrites sur des coupes à boire, contribuaient à personnaliser des offrandes ou à leur donner de la valeur. Le sanctuaire et les pratiques rituelles qui s'y déroulaient offraient un cadre propice à l'usage précoce de l'écriture, au moment où la polis grecque se constituait.

Le burnout concerne 20 pour cent de la population active

Epuisement émotionnel, déshumanisation progressive de la relation avec l'autre et un sentiment d'échec professionnel. Le burnout est tout ça à la fois. La difficulté est de déceler à temps ces symptômes qui peuvent mettre parfois des mois, voire des années à se déclarer. Définition et tour d'horizon du burnout.

'Greek' and 'Roman' in Latin Medical Texts. Studies in Cultural Change and Exchange in Ancient Medicine : [Proceedings of the 10th International Conference "Ancient Latin Medical Texts", Lausanne, 2010, November 3rd-6th November]

Latin medical texts transmit medical theories and practices that originated mainly in Greece. This interaction took place through juxtaposition, assimilation and transformation of ideas. 'Greek' and 'Roman' in Latin Medical Texts studies the ways in which this cultural interaction influenced the development of the medical profession and the growth of knowledge of human and animal bodies, and especially how it provided the foundations for innovations in the areas of anatomy, pathology and pharmacology, from the earliest Latin medical texts until well into the medieval world.

Fonctions psychologiques du religieux: Cent ans après "Varieties" de William James

La première traduction en français de « The Varieties of Religious Experience » fut publiée en 1906 et elle connut aussitôt un très grand retentissement. Dans cet ouvrage, William James affirme: « D'un point de vue tout psychologique, la religion est une fonction éternelle de l'esprit humain ». Toutefois, caractériser la religion par une fonction si fondamentale, sous-jacente à tous les systèmes de croyances, ne conduit pas James à porter un regard dévalorisant sur la multiplicité des formes religieuses. Au contraire, il y voit l'expression de la variété des combinaisons possibles du religieux avec la vie psychique sous ses différents aspects. Ce livre a pour but non seulement de relire William James un siècle après la publication de Varieties, mais aussi de préciser, sur la base des connaissances actuelles, quelles sont les fonctions psychologiques du religieux.

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.

The fourth "Melanoma Bridge Meeting" took place in Naples, December 3-6th, 2014. The four topics discussed at this meeting were: Molecular and Immunological Advances, Combination Therapies, News in Immunotherapy, and Tumor Microenvironment and Biomarkers. Until recently systemic therapy for metastatic melanoma patients was ineffective, but recent advances in tumor biology and immunology have led to the development of new targeted and immunotherapeutic agents that prolong progression-free survival (PFS) and overall survival (OS). New therapies, such as mitogen-activated protein kinase (MAPK) pathway inhibitors as well as other signaling pathway inhibitors, are being tested in patients with metastatic melanoma either as monotherapy or in combination, and all have yielded promising results. These include inhibitors of receptor tyrosine kinases (BRAF, MEK, and VEGFR), the phosphatidylinositol 3 kinase (PI3K) pathway [PI3K, AKT, mammalian target of rapamycin (mTOR)], activators of apoptotic pathway, and the cell cycle inhibitors (CDK4/6). Various locoregional interventions including radiotherapy and surgery are still valid approaches in treatment of advanced melanoma that can be integrated with novel therapies. Intrinsic, adaptive and acquired resistance occur with targeted therapy such as BRAF inhibitors, where most responses are short-lived. Given that the reactivation of the MAPK pathway through several distinct mechanisms is responsible for the majority of acquired resistance, it is logical to combine BRAF inhibitors with inhibitors of targets downstream in the MAPK pathway. For example, combination of BRAF/MEK inhibitors (e.g., dabrafenib/trametinib) have been demonstrated to improve survival compared to monotherapy. Application of novel technologies such sequencing have proven useful as a tool for identification of MAPK pathway-alternative resistance mechanism and designing other combinatorial therapies such as those between BRAF and AKT inhibitors. Improved survival rates have also been observed with immune-targeted therapy for patients with metastatic melanoma. Immune-modulating antibodies came to the forefront with anti-CTLA-4, programmed cell death-1 (PD-1) and PD-1 ligand 1 (PD-L1) pathway blocking antibodies that result in durable responses in a subset of melanoma patients. Agents targeting other immune inhibitory (e.g., Tim-3) or immune stimulating (e.g., CD137) receptors and other approaches such as adoptive cell transfer demonstrate clinical benefit in patients with melanoma as well. These agents are being studied in combination with targeted therapies in attempt to produce longer-term responses than those more typically seen with targeted therapy. Other combinations with cytotoxic chemotherapy and inhibitors of angiogenesis are changing the evolving landscape of therapeutic options and are being evaluated to prevent or delay resistance and to further improve survival rates for this patient population. This meeting's specific focus was on advances in combination of targeted therapy and immunotherapy. Both combination targeted therapy approaches and different immunotherapies were discussed. Similarly to the previous meetings, the importance of biomarkers for clinical application as markers for diagnosis, prognosis and prediction of treatment response was an integral part of the meeting. The overall emphasis on biomarkers supports novel concepts toward integrating biomarkers into contemporary clinical management of patients with melanoma across the entire spectrum of disease stage. Translation of the knowledge gained from the biology of tumor microenvironment across different tumors represents a bridge to impact on prognosis and response to therapy in melanoma.